Does this job make me look fat? A Gallup-Healthways survey takes a look at which jobs have high rates of obesity. And it's bad news for bus drivers.» Read More
Well, figuring out how to profit off it, anyway. Here’s Cramer’s pick.
Allscripts could see tremendous growth when a new Medicare bill is passed.
So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.
Fresenius might cash in once the new bill passes.
Some lucky companies will split up $454 billion this year. But who?
When combing through Barron's over the weekend I always make it a point to check out the "Short Interest" tables when they appear. I'm curious, in particular, about the ups and downs in Dendreon. Right now it's 39th on Barron's list of the Top-40 largest short positions.
On another ugly day for the stock markets, beaten down shares of Dow component Merck rallied. The stock started picking up steam after the news broke late this morning that its late-stage experimental migraine headache drug essentially works just as well as an existing drug, but with fewer side effects.
FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."
Credit Suisse is out today with a "fat" report on obesity. Nearly 200 pages. But besides its size, the research also stands out as one of the most unique pieces of Wall Street analysis I've ever seen.
A new kind of contract, which would be renewed each year, will allow companies to buy a full shipment of Tamiflu at the prevailing wholesale price.
For the second time in three days the Food and Drug Administration has delayed making a decision on drugs that it had put on a fast track. First, the agency put off a ruling on Lilly's bloodthinner Effient and then this morning Merck announced the FDA is not ready to approve its cervical cancer vaccine Gardasil for older women.
Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days.
As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...
You need health insurance, period. So why do employers make it so painstaking to figure out?
Lance Armstrong is among the most relevant retired athletes, having raised tens of millions of dollars for cancer research through his foundation. His slogan "Livestrong" has been featured on everything from those familiar yellow bracelets to a whole line of Nike product, in which 100 percent of the profits go to charity.
It never ceases to amaze me who reads Pharma's Market. Like the Stanford University professor who wrote to set the record straight regarding my coverage from ASCO of the brain cancer vaccine from Pfizer and Avant.
I'm at the Needham & Company biotech conference in New York City. Whenever possible I like to attend events like this. It's a good place to get story ideas. The Needham meeting is competing this year with a similar one being put on by Goldman Sachs in Laguna Beach, CA.
Pfizer shares continue to trade at new nearly 11-year lows over concerns the dividend might get cut, in addition to the lack of anything visible to replace Lipitor when it goes generic in a couple years or so. But on two of the op-ed pages in Wednesday's "Wall Street Journal" Pfizer got a plug.
Cancer, diabetes and Alzheimer's Disease. Three of the biggest areas of unmet medical need have been or will be in focus at a series of important scientific meetings in June or July.
First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.